We are live on ! Find out more
BBH icon

VanEck Biotech ETF
BBH

90 hedge funds and large institutions have $167M invested in VanEck Biotech ETF in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 29 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 9

8% more funds holding

Funds holding: 83 → 90 (+7)

2% less call options, than puts

Call options by funds: $4.19M | Put options by funds: $4.28M

21% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 29

21.1% less ownership

Funds ownership: 45.23% → 24.14% (-21%)

43% less capital invested

Capital invested by funds: $294M → $167M (-$127M)

Holders
90
Holders Change
+7
Holders Change %
+8.43%
% of All Funds
2.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
23
Reduced
29
Closed
9
Calls
$4.19M
Puts
$4.28M
Net Calls
-$87K
Net Calls Change
+$2.9M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$5.67M
2
LPL Financial
LPL Financial
California
+$3.92M
3
JP Morgan Chase
JP Morgan Chase
New York
+$3.91M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.87M
5
BPC
Banque Pictet & Cie
Switzerland
+$2.35M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$147M
2
CS
Credit Suisse
Switzerland
-$13.6M
3
TRCT
Tower Research Capital (TRC)
New York
-$3.49M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.08M
5
HF
HRT Financial
New York
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
SHJ
76
Sharkey, Howes & Javer
Colorado
$44K – – –
KPCM
77
Kings Point Capital Management
New York
$34K – – –
AF
78
Arrow Financial
New York
$32K – – –
US Bancorp
79
US Bancorp
Minnesota
$28K +$8.94K +73 +49%
M
80
MOTCO
Texas
$25K -$12.3K -100 -33%
AIP
81
Ameritas Investment Partners
Nebraska
$16K – – –
EDRE
82
Edmond de Rothschild (Europe)
Luxembourg
$16K – – –
SJIM
83
St. Johns Investment Management
Florida
$13K -$6.13K -50 -33%
OFS
84
Orrstown Financial Services
Pennsylvania
$13K – – –
WA
85
WFG Advisors
Texas
$13K – – –
PIM
86
Parasol Investment Management
Illinois
$10K – – –
ACM
87
Argentus Capital Management
Texas
$1K – – –
AIA
88
Allegis Investment Advisors
Idaho
$1K +$1.23K +10 New
MFW
89
Mosaic Family Wealth
Missouri
$1K +$1.47K +12 New
UCFA
90
United Capital Financial Advisors
Texas
– -$653K -5,715 Closed
SFM
91
Signet Financial Management
New Jersey
– -$296K -2,586 Closed
NCM
92
Niemann Capital Management
Nevada
– -$285K -2,493 Closed
Envestnet Asset Management
93
Envestnet Asset Management
Illinois
– -$116K -1,012 Closed
KCM
94
Karp Capital Management
California
– -$74K -650 Closed
KF
95
Krilogy Financial
Missouri
– -$43K -380 Closed
HCMT
96
Highland Capital Management (Tennessee)
Tennessee
– -$12K -105 Closed
AP
97
Advisors Preferred
Maryland
– -$12K -101 Closed
RIA
98
Regal Investment Advisors
Michigan
– -$2K -20 Closed
1 2 3
4

BBH Hedge Fund Activity: Q4 2015 in Review

90 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q4 2015, worth a combined $167M — down 43% from $294M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new BBH positions and 9 closed out — a net gain of 7 holders — while 23 added to existing stakes and 29 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $5.67M. The largest seller was Goldman Sachs, cutting an estimated $147M.

  • 90 institutional investors held VanEck Biotech ETF (BBH) as of Q4 2015, up from 83 in Q3 2015.
  • Funds reported $167M of VanEck Biotech ETF stock for Q4 2015, down 43% quarter-over-quarter.
  • 16 funds opened new VanEck Biotech ETF positions in Q4 2015 and 9 closed out, a net change of +7 holders.
  • The largest VanEck Biotech ETF buyer in Q4 2015 was Morgan Stanley, an estimated $5.67M added.
  • The largest VanEck Biotech ETF seller in Q4 2015 was Goldman Sachs, an estimated $147M sold.

Based on aggregated 13F filings for Q4 2015.